A Phase I/II Study of Syk Inhibitor Entospletinib (GS-9973) in Combination With Obinutuzumab in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) and B-Cell Malignancies
Latest Information Update: 10 Aug 2023
At a glance
- Drugs Entospletinib (Primary) ; Obinutuzumab (Primary)
- Indications B-cell prolymphocytic leukaemia; Chronic lymphocytic leukaemia; Follicular lymphoma; Hairy cell leukaemia; Mantle-cell lymphoma; Marginal zone B-cell lymphoma; Non-Hodgkin's lymphoma; Richter's syndrome; Waldenstrom's macroglobulinaemia
- Focus Adverse reactions; Therapeutic Use
- 14 Dec 2021 Results presented at the 63rd American Society of Hematology Annual Meeting and Exposition
- 30 Jun 2021 Results assessing Proapoptotic and immunomodulatory effects of SYK inhibitor entospletinib in combination with obinutuzumab in patients with chronic lymphocytic leukemia, published in the British Journal of Clinical Pharmacology
- 29 Apr 2021 Status changed from active, no longer recruiting to completed.